Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03950154 |
Title化疗联合自体细胞免疫疗法治疗复发性和转移性结直肠癌的研究 | 阶段
第三阶段
|
Date Added 2019-05-15 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Bevacizumab Injection [Avastin], capecitabine, oxaliplatin, PD1-T cells |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03947385 |
TitleIDE196对携带GNAQ/11突变或PRKC融合的实体瘤患者的研究 | 阶段
Phase 1, Phase 2
|
Date Added 2019-05-13 |
地点
California, United States
New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States 澳大利亚 加拿大 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Binimetinib, Crizotinib, IDE196 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03829462 |
Title评估转移性结直肠癌患者服用瑞戈非尼-伊立替康复方制剂与单用瑞戈非尼的效果 | 阶段
第三阶段
|
Date Added 2019-02-04 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Irinotecan, Regorafenib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04014530 |
TitlePembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study | 阶段
第 1 阶段
|
Date Added 2019-07-10 |
地点
荷兰
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Ataluren + Pembrolizumab, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT04096417 |
TitlePemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | 阶段
第二阶段
|
Date Added 2019-09-19 |
地点
Arizona, United States
Georgia, United States Minnesota, United States North Carolina, United States Tennessee, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pemigatinib |
标签
MSS/ MMRp
|
| NCT ID NCT04874259 |
TitleLT治疗无法切除的结直肠肝转移瘤 | 阶段
不适用
|
Date Added 2021-05-05 |
地点
大韩民国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04595266 |
Title化疗栓塞（Lifepearls-伊立替康）在结直肠癌和转移性疾病患者中的应用 | 阶段
第二阶段
|
Date Added 2020-10-20 |
地点
西班牙
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04589845 |
Title肿瘤诊断精准免疫肿瘤学和体细胞靶向合理性（TAPISTRY）平台研究 | 阶段
第二阶段
|
Date Added 2020-10-19 |
地点
Alabama, United States
Arizona, United States California, United States Colorado, United States Delaware, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Maine, United States Maryland, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States 澳大利亚 比利时 巴西 加拿大 中国 丹麦 法国 德国 香港 以色列 意大利 日本 大韩民国 新西兰 波兰 葡萄牙 波多黎各 新加坡 南非 西班牙 瑞士 台湾 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
Alectinib, Atezolizumab, Belvarafenib, Entrectinib, Idasanutlin, Inavolisib, Ipatasertib, Pralsetinib, Trastuzumab emtansine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03310008 |
TitleDose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases | 阶段
第 1 阶段
|
Date Added 2017-10-16 |
地点
比利时
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
NKR-2 cells |
标签
MSS/ MMRp
|
| NCT ID NCT03984578 |
Title大肠癌机会之窗研究 | 阶段
第二阶段
|
Date Added 2019-06-13 |
地点
新加坡
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Capecitabine/ 5-FU, CapeOX, Pembrolizumab, Eloxatin, Keytruda |
标签
MSI-H/ MMRd, MSS/ MMRp
|
